Here, we present the results of a pilot study evaluating the efficacy of the anti-PD-1 drug pembrolizumab in seven patients with TCRLBCL (n = 3) or EBV+ DLBCL, NOS (n = 4). All patients had disease relapsed or were refractory to standard chemo-immunotherapy and had received at least two previous lines (range 2–5). Checkpoint inhibitors may represent a potential therapeutic alternative in subsets of patients who do not benefit most of CAR T-cell therapy.
Pembrolizumab as salvage treatment for T-cell/histiocyte-rich and Epstein-Barr virus-positive large B-cell lymphoma
Schena, A;Quaglia, F M;Parisi, A;Ferrarini, I;Moioli, A;Tagliavini, E;Bernardelli, A;Visco, C
2024-01-01
Abstract
Here, we present the results of a pilot study evaluating the efficacy of the anti-PD-1 drug pembrolizumab in seven patients with TCRLBCL (n = 3) or EBV+ DLBCL, NOS (n = 4). All patients had disease relapsed or were refractory to standard chemo-immunotherapy and had received at least two previous lines (range 2–5). Checkpoint inhibitors may represent a potential therapeutic alternative in subsets of patients who do not benefit most of CAR T-cell therapy.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
